The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
Open accessAbstract
BACKGROUND: A complete remission is essential for prolonging survival in patients with acute myeloid leukemia (AML). Daunorubicin is a cornerstone of the induction regimen, but the optimal dose is unknown. In older patients, it is usual to give daunorubicin at a dose of 45 to 50 mg per square meter of body-surface area. METHODS: Patients in whom AML or high-risk refractory anemia had been newly diagnosed and who were 60 to 83 years of age (median, 67) were randomly assigned to receive cytarabine, at a dose of 200 mg per square meter by continuous infusion for 7 days, plus daunorubicin for 3 days, either at the conventional dose of 45 mg per square meter (411 patients) or at an escalated dose of 90 mg per square meter (402 patients); this treatment was followed by a second cycle of cytarabine at a dose of 1000 mg per square meter every 12 hours [DOSAGE ERROR CORRECTED] for 6 days. The primary end point was event-free survival. RESULTS: The complete remission rates were 64% in the group that received the escalated dose of daunorubicin and 54% in the group that received the conventional dose (P=0.002); the rates of remission after the first cycle of induction treatment were 52% and 35%, respectively (P<0.001). There was no significant difference between the two groups in the incidence of hematologic toxic effects, 30-day mortality (11% and 12% in the two groups, respectively), or the incidence of moderate, severe, or life-threatening adverse events (P=0.08). Survival end points in the two groups did not differ significantly overall, but patients in the escalated-treatment group who were 60 to 65 years of age, as compared with the patients in the same age group who received the conventional dose, had higher rates of complete remission (73% vs. 51%), event-free survival (29% vs. 14%), and overall survival (38% vs. 23%). CONCLUSIONS: In patients with AML who are older than 60 years of age, escalation of the dose of daunorubicin to twice the conventional dose, with the entire dose administered in the first induction cycle, effects a more rapid response and a higher response rate than does the conventional dose, without additional toxic effects. (Current Controlled Trials number, ISRCTN77039377; and Netherlands National Trial Register number, NTR212.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia
Mayer, R. J., Davis, R. B., Schiffer, C. A., Berg, D. T., Powell, B. L., Schulman, P., Omura, G. A., Moore, J. O., McIntyre, O. R., & Frei, E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311402 · Cited by 1,427
Age and acute myeloid leukemia
Appelbaum, F. R., Gundacker, H., Head, D. R., Slovak, M. L., Willman, C. L., Godwin, J. E., Anderson, J. E., & Petersdorf, S. H. (2006) · Blood · doi:10.1182/blood-2005-09-3724 · Cited by 1,350
Lowenberg, B., Downing, J. R., & Burnett, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909303411407 · Cited by 1,217
Kantarjian, H., O'Brien, S., Cortes, J., Giles, F., Faderl, S., Jabbour, E., Garcia‐Manero, G., Wierda, W., Pierce, S., Shan, J., et al. (2006) · Cancer · doi:10.1002/cncr.21723 · Cited by 610
Breems, D. A., Van Putten, W. L. J., De Greef, G. E., Van Zelderen-Bhola, S. L., Gerssen-Schoorl, K. B. J., Mellink, C. H. M., Nieuwint, A., Jotterand, M., Hagemeijer, A., Beverloo, H. B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0259 · Cited by 580
Self-citationGoldstone, A. H., Burnett, A. K., Wheatley, K., Smith, A. G., Hutchinson, R. M., & Clark, R. E. (2001) · Blood · doi:10.1182/blood.v98.5.1302 · Cited by 438
Löwenberg, B., Zittoun, R., Kerkhofs, H., Jehn, U., Abels, J., Debusscher, L., Cauchie, C., Peetermans, M., Solbu, G., & Suciu, S. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.9.1268 · Cited by 384
Self-citationBaer, M. R., George, S. L., Dodge, R. K., O'Loughlin, K. L., Minderman, H., Caligiuri, M. A., Anastasi, J., Powell, B. L., Kolitz, J. E., Schiffer, C. A., et al. (2002) · Blood · doi:10.1182/blood.v100.4.1224.h81602001224_1224_1232 · Cited by 366
Büchner, T., Berdel, W. E., Haferlach, C., Haferlach, T., Schnittger, S., Müller-Tidow, C., Braess, J., Spiekermann, K., Kienast, J., Staib, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4245 · Cited by 338
Godwin, J. E., Kopecky, K. J., Head, D. R., Willman, C. L., Leith, C. P., Hynes, H. E., Balcerzak, S. P., & Appelbaum, F. R. (1998) · Blood · doi:10.1182/blood.v91.10.3607 · Cited by 312
Dombret, H., Chastang, C., Fenaux, P., Reiffers, J., Bordessoule, D., Bouabdallah, R., Mandelli, F., Ferrant, A., Auzanneau, G., Tilly, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506223322504 · Cited by 308
Self-citationFröhling, S., Schlenk, R. F., Kayser, S., Morhardt, M., Benner, A., Döhner, K., Döhner, H., & for the German-Austrian AML Study Group (2006) · Blood · doi:10.1182/blood-2006-04-014324 · Cited by 300
Rowe, J. M., Neuberg, D., Friedenberg, W., Bennett, J. M., Paietta, E., Makary, A. Z., Liesveld, J. L., Abboud, C. N., Dewald, G., Hayes, F. A., et al. (2004) · Blood · doi:10.1182/blood-2003-05-1686 · Cited by 277
Wheatley, K., Brookes, C. L., Howman, A. J., Goldstone, A. H., Milligan, D. W., Prentice, A. G., Moorman, A. V., Burnett, A. K., & on behalf of the United Kingdom National Cancer Research Institute Haematological Oncology Clinical Studies Group and Acute Myeloid Leukaemia Subgroup (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07663.x · Cited by 236
Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients
Estey, E. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2731 · Cited by 235
Stone, R. M., Berg, D. T., George, S. L., Dodge, R. K., Paciucci, P. A., Schulman, P. P., Lee, E. J., Moore, J. O., Powell, B. L., Baer, M. R., et al. (2001) · Blood · doi:10.1182/blood.v98.3.548 · Cited by 211
Anderson, J. E., Kopecky, K. J., Willman, C. L., Head, D., O'Donnell, M. R., Luthardt, F. W., Norwood, T. H., Chen, I.-M., Balcerzak, S. P., Johnson, D. B., et al. (2002) · Blood · doi:10.1182/blood-2001-12-0354 · Cited by 190
Kahn, S. B., Begg, C. B., Mazza, J. J., Bennett, J. M., Bonner, H. S., & Glick, J. H. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.8.865 · Cited by 144
Burnett, A. K., Milligan, D. W., Goldstone, A. H., Prentice, A. G., McMullin, M., Dennis, M. W., Sellwood, E., Pallis, M., Russell, N. H., Hills, R. K., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07604.x · Cited by 139
van der Holt, B., Breems, D. A., Beverloo, H. B., et al. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06403.x · Cited by 69
Prognostic Factors in Elderly Patients with AML and the Implications for Treatment
Erba, H. P. (2007) · Hematology · doi:10.1182/asheducation-2007.1.420 · Cited by 58
Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia
Baz, R., Rodriguez, C. P., Fu, A. Z., Jawde, R. M. A., Kalaycio, M. E., Advani, A. S., Sobecks, R. M., & Sekeres, M. A. (2007) · Cancer · doi:10.1002/cncr.22976 · Cited by 32
Research works printed but not linked: 3
- 10.1016/S0145-2126(01)00006-6 · doi:10.1016/s0145-2126(01)00006-6
- 10.1200/JCO.2003.02.133 · doi:10.1200/jco.2003.02.133
- Lowenberg B, 1998, J Clin Oncol, 16, 872, 10.1200/JCO.1998.16.3.872 · doi:10.1200/jco.1998.16.3.872
Cited by
Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
Self-citationDöhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Self-citationPrognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H., Sun, Z., Racevskis, J., Van Vlierberghe, P., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112304 · Cited by 1,946
Castaigne, S., Pautas, C., Terré, C., Raffoux, E., Bordessoule, D., Bastie, J.-N., Legrand, O., Thomas, X., Turlure, P., Reman, O., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60485-1 · Cited by 1,015
Therapeutic Advances in Acute Myeloid Leukemia
Burnett, A., Wetzler, M., & Löwenberg, B. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.1820 · Cited by 787
Self-citation
Metadata
- Authors
- Löwenberg, B., Ossenkoppele, G. J., van Putten, W., Schouten, H. C., Graux, C., Ferrant, A., Sonneveld, P., Maertens, J., Jongen-Lavrencic, M., von Lilienfeld-Toal, M., Biemond, B. J., Vellenga, E., Kooy, M. V. M., Verdonck, L. F., Beck, J., Döhner, H., Gratwohl, A., Pabst, T., & Verhoef, G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-09-24
- Volume
- 361
- Issue
- 13
- Pages
- 1235-1248
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2079025304
- Cited by
- 828
- References
- 24
- FWCI
- 37.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.